JP2013511287A5 - - Google Patents

Download PDF

Info

Publication number
JP2013511287A5
JP2013511287A5 JP2012540160A JP2012540160A JP2013511287A5 JP 2013511287 A5 JP2013511287 A5 JP 2013511287A5 JP 2012540160 A JP2012540160 A JP 2012540160A JP 2012540160 A JP2012540160 A JP 2012540160A JP 2013511287 A5 JP2013511287 A5 JP 2013511287A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
composition according
diabetes
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012540160A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013511287A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/057890 external-priority patent/WO2011063414A1/en
Publication of JP2013511287A publication Critical patent/JP2013511287A/ja
Publication of JP2013511287A5 publication Critical patent/JP2013511287A5/ja
Pending legal-status Critical Current

Links

JP2012540160A 2009-11-23 2010-11-23 ポリペプチド・コンジュゲート Pending JP2013511287A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26375209P 2009-11-23 2009-11-23
US61/263,752 2009-11-23
PCT/US2010/057890 WO2011063414A1 (en) 2009-11-23 2010-11-23 Polypeptide conjugate

Publications (2)

Publication Number Publication Date
JP2013511287A JP2013511287A (ja) 2013-04-04
JP2013511287A5 true JP2013511287A5 (enExample) 2013-11-14

Family

ID=44060086

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012540160A Pending JP2013511287A (ja) 2009-11-23 2010-11-23 ポリペプチド・コンジュゲート

Country Status (11)

Country Link
US (1) US20140066370A1 (enExample)
EP (1) EP2504021A4 (enExample)
JP (1) JP2013511287A (enExample)
KR (1) KR20120116942A (enExample)
CN (1) CN102781458A (enExample)
AU (1) AU2010321587A1 (enExample)
CA (1) CA2781672A1 (enExample)
IL (1) IL219948A0 (enExample)
MX (1) MX2012005912A (enExample)
RU (1) RU2012126101A (enExample)
WO (1) WO2011063414A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104945499B (zh) * 2014-03-31 2019-12-10 博瑞生物医药(苏州)股份有限公司 结构修饰的glp-1类似物及其制备方法
TWI772252B (zh) * 2014-09-16 2022-08-01 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
CN106554404B (zh) * 2015-09-25 2020-11-20 博瑞生物医药(苏州)股份有限公司 艾塞那肽修饰物及其用途
WO2022002409A1 (en) * 2020-07-02 2022-01-06 Sanofi Glp-1r agonistic peptides with reduced activity
TW202620039A (zh) * 2020-12-18 2026-05-16 丹麥商諾佛 儂迪克股份有限公司 Glp-1及澱粉素受體之共促效劑之用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DE69921102T2 (de) 1998-03-05 2006-02-02 Chiron Corp., Emeryville Verfahren zur verbesserung der serum-halbwertszeit von biologisch aktiven molekülen
JP2002538084A (ja) 1999-01-14 2002-11-12 アミリン・ファーマシューティカルズ,インコーポレイテッド グルカゴンを抑制する方法
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
PT1180121E (pt) 1999-05-17 2004-03-31 Conjuchem Inc Peptidos insulinotropicos de longa duracao
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
KR20140011431A (ko) 2004-02-11 2014-01-28 아밀린 파마슈티칼스, 엘엘씨. 선택가능한 특성을 갖는 하이브리드 폴리펩티드
RU2385878C2 (ru) 2004-02-11 2010-04-10 Амилин Фармасьютикалз, Инк. Пептид, обладающий свойствами амилина (варианты), и его применение (варианты)
US7465234B2 (en) * 2004-09-13 2008-12-16 The Boeing Company Hybrid fastening system and associated method of fastening
CA2597649A1 (en) * 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
MX2008002028A (es) * 2005-08-11 2008-03-27 Amylin Pharmaceuticals Inc Polipeptidos hibridos con propiedades de seleccion.
EP1922336B1 (en) 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
US8039432B2 (en) 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
US20070238669A1 (en) 2006-01-11 2007-10-11 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes related conditions
WO2007114838A1 (en) 2006-03-31 2007-10-11 Amylin Pharmaceuticals, Inc. Amylin and amylin agonists for treating psychiatric diseases and disorders
MX2008015107A (es) * 2006-05-26 2008-12-09 Amylin Pharmaceuticals Inc Composicion y metodos para el tratamiento de insuficiecia cardiaca congestiva.
EP2021014A1 (en) 2006-05-26 2009-02-11 Brystol-Myers Squibb Company Sustained release glp-1 receptor modulators
CN101125207B (zh) 2006-11-14 2012-09-05 上海华谊生物技术有限公司 带有聚乙二醇基团的艾塞丁或其类似物及其制剂和用途
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
WO2010118384A2 (en) * 2009-04-10 2010-10-14 Amylin Pharmaceuticals, Inc. Amylin agonist compounds for estrogen-deficient mammals
US9249181B2 (en) * 2010-09-13 2016-02-02 Amylin Pharmaceuticals, Llc C-terminal amidation of polypeptides
US10755005B1 (en) 2015-12-31 2020-08-25 Dassault Systemes Solidworks Corporation Providing a single command to create multiple CAD features

Similar Documents

Publication Publication Date Title
RU2470016C2 (ru) Производное бипиразола
JP2006143751A5 (enExample)
JP2011503152A5 (enExample)
JP2009542702A5 (enExample)
FI4349369T3 (fi) Lääkkeen biologisen hyötyosuuden lisääminen naltreksonihoidossa
RU2016122957A (ru) Способы применения интерлейкина-10 для лечения заболеваний и расстройств
JP2011528333A5 (enExample)
JP2009542699A5 (enExample)
RU2017145348A (ru) Селективные соединения пептида yy и их применения
JP2008007519A5 (enExample)
JP2018531938A5 (enExample)
JP2011225596A5 (enExample)
JP2013509411A5 (enExample)
JP2020536854A5 (enExample)
JP2017500289A5 (enExample)
JP2011068653A5 (enExample)
JP2013541583A5 (enExample)
CN108451941A (zh) 治疗糖尿病的组合物和方法
JP2017526695A5 (enExample)
RU2012126101A (ru) Полипептидный конъюгат
JP2023531675A5 (enExample)
JP2015517458A5 (enExample)
JP2015508765A5 (enExample)
CA2944837A1 (en) Cyclohexenyl compounds, compositions comprising them and uses thereof
JP2009506043A5 (enExample)